Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases- Lead target ...

As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in ...

Multidrug-resistant bacteria pose a major threat to human health. Manipulation of bacterial genes at the transcriptional level is a potential strategy to fight antibiotic-resistant bacterial ...

In a recent publication in Cell Reports Medicine, a collaborative research team led by Chen-Yu Zhang and Huan Wang at Nanjing ...

Multidrug-resistant bacteria pose a major threat to human health. Manipulation of bacterial genes at the transcriptional ...

Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025 ...

Given the growing antibiotic resistance crisis, novel ways to target bacterial infections are becoming increasingly important. One potential strategy is to manipulate bacterial genes at the ...

The US biotech has just reported phase 2 trial results with the small, interfering RNA (siRNA) gene-silencing drug showing that it an cause a 90% or greater reduction in Lp(a) levels – a risk ...

Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...